Hardie, D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25, 1895–1908 (2011).
Munday, M.R., Campbell, D.G., Carling, D. & Hardie, D.G. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175, 331–338 (1988).
Koo, S.H. et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109–1111 (2005).
Sambandam, N. & Lopaschuk, G.D. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog. Lipid Res. 42, 238–256 (2003).
Winder, W.W. et al. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J. Appl. Physiol. 82, 219–225 (1997).
Minokoshi, Y. et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339–343 (2002).
Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288–1295 (2002).
Kishi, K. et al. AMP-activated protein kinase is activated by the stimulations of Gq-coupled receptors. Biochem. Biophys. Res. Commun. 276, 16–22 (2000).
Huypens, P., Quartier, E., Pipeleers, D. & Van de Casteele, M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur. J. Pharmacol. 518, 90–95 (2005).
Hardie, D.G. & Hawley, S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23, 1112–1119 (2001).
Oakhill, J.S. et al. β-subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl. Acad. Sci. USA 107, 19237–19241 (2010).
Suter, M. et al. Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem. 281, 32207–32216 (2006).
Hawley, S.A. et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003).
Shaw, R.J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642–1646 (2005).
Hawley, S.A. et al. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2, 9–19 (2005).
Herrero-Martín, G. et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28, 677–685 (2009).
Kim, E.J. et al. RORα-induced activation of AMP-activated protein kinase results in attenuation of hepatic steatosis. Hepatology 55, 1379–1388 (2012).
Lee, C.G. et al. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology 142, 1206–1217 e7 (2012).
Linher-Melville, K., Zantinge, S. & Singh, G. Liver kinase B1 expression (LKB1) is repressed by estrogen receptor α (ERα) in MCF-7 human breast cancer cells. Biochem. Biophys. Res. Commun. 417, 1063–1068 (2012).
Nath-Sain, S. & Marignani, P.A. LKB1 catalytic activity contributes to estrogen receptor α signaling. Mol. Biol. Cell 20, 2785–2795 (2009).
Germain, P., Staels, B., Dacquet, C., Spedding, M. & Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58, 685–704 (2006).
Fu, Y., Luo, L., Luo, N., Zhu, X. & Garvey, W.T. NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance. J. Biol. Chem. 282, 31525–31533 (2007).
Chao, L.C. et al. Nur77 coordinately regulates expression of genes linked to glucose metabolism in skeletal muscle. Mol. Endocrinol. 21, 2152–2163 (2007).
Pei, L. et al. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. Nat. Med. 12, 1048–1055 (2006).
Chao, L.C. et al. Insulin resistance and altered systemic glucose metabolism in mice lacking Nur77. Diabetes 58, 2788–2796 (2009).
Zhan, Y. et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat. Chem. Biol. 4, 548–556 (2008).
Crute, B.E., Seefeld, K., Gamble, J., Kemp, B.E. & Witters, L.A. Functional domains of the α1 catalytic subunit of the AMP-activated protein kinase. J. Biol. Chem. 273, 35347–35354 (1998).
Li, Y. et al. Molecular recognition of nitrated fatty acids by PPARγ. Nat. Struct. Mol. Biol. 15, 865–867 (2008).
Pike, A.C. et al. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J. 18, 4608–4618 (1999).
Renaud, J.P. et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681–689 (1995).
Shiau, A.K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–937 (1998).
Baas, A.F. et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 22, 3062–3072 (2003).
Xie, Z., Dong, Y., Scholz, R., Neumann, D. & Zou, M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-ζ is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117, 952–962 (2008).
Karuman, P. et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol. Cell 7, 1307–1319 (2001).
Xie, Z. et al. Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. Mol. Cell. Biol. 29, 3582–3596 (2009).
Tiainen, M., Vaahtomeri, K., Ylikorkala, A. & Makela, T.P. Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum. Mol. Genet. 11, 1497–1504 (2002).
Boudeau, J. et al. MO25α/β interact with STRADα/β enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 22, 5102–5114 (2003).
Sakamoto, K., Goransson, O., Hardie, D.G. & Alessi, D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 287, E310–E317 (2004).
Viollet, B. et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol. (Lond.) 574, 41–53 (2006).
Coleman, D.L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141–148 (1978).
Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L. & Ramarao, P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52, 313–320 (2005).
Gilbert, E.R., Fu, Z. & Liu, D. Development of a nongenetic mouse model of type 2 diabetes. Exp. Diabetes Res. 2011, 416254 (2011).
Deepa, S.S. et al. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCγ signaling pathway. Mol. Endocrinol. 25, 1773–1785 (2011).
Kimball, S.R., Siegfried, B.A. & Jefferson, L.S. Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase. J. Biol. Chem. 279, 54103–54109 (2004).